Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 10/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | LAP3 | P28838 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23992574 | 1.00 | BTN3A1 (0.53) | BTN3A1MAPK1ANPEPLAP3KMT2A | |
| SCHEMBL12870471 | 1.00 | BTN3A1 (0.53) | BTN3A1MAPK1ANPEPLAP3KMT2A | |
| SCHEMBL25387275 | 1.00 | BTN3A1 (0.53) | BTN3A1MAPK1ANPEPLAP3KMT2A | |
| SCHEMBL20248041 | 0.88 | BTN3A1 (0.55) | BTN3A1ANPEPLAP3KMT2AMEN1 | |
| SCHEMBL524066 | 0.88 | BTN3A1 (0.55) | BTN3A1ANPEPLAP3KMT2AMEN1 | |
| SCHEMBL15588619 | 0.88 | BTN3A1 (0.55) | BTN3A1ANPEPLAP3KMT2AMEN1 | |
| SCHEMBL524067 | 0.88 | BTN3A1 (0.55) | BTN3A1ANPEPLAP3KMT2AMEN1 | |
| SCHEMBL16374214 | 0.88 | BTN3A1 (0.55) | BTN3A1ANPEPLAP3KMT2AMEN1 | |
| SCHEMBL14627743 | 0.88 | SMN1; SMN2 (0.42) | BTN3A1KMT2AMEN1 | |
| SCHEMBL20773105 | 0.88 | ANPEP (0.44) | BTN3A1ANPEPLAP3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129112-A1 | Novel Prodrugs Derived from Nicotinic Acid and Ribose | MITOPOWER, INC. | 2025-04-24 | — | — | US | disclosed |
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD SCIENCES INC (US) | 2025-02-20 | — | — | US | disclosed |
| US-12168673-B2 | Prodrugs derived from nicotinic acid and ribose | MITOPOWER, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| EP-4463158-A2 | NOVEL PRODRUGS DERIVED FROM NICOTINIC ACID AND RIBOSE | Mitopower, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118922189-A | Novel prodrugs derived from niacin and ribose | 线粒体能量有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-114008058-B | Prodrugs of CDK inhibitors for the treatment of cancer | 润佳（苏州）医药科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-117362276-A | Tropomyosin receptor kinase A inhibitor and preparation method and application thereof | 复旦大学 | 2024-01-09 | — | — | CN | disclosed |
| EP-4282482-A2 | Nucleoside phosphoramidate prodrugs | Gilead Sciences, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-111848579-B | Prodrugs of 4- (2, 6-dichlorobenzoylamino) -N- (4-piperidinyl) -1H-pyrazole-3-carboxamide | 君实润佳(上海)医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230279035-A1 | Novel Prodrugs Derived from Nicotinic Acid and Ribose | MITOPOWER, INC. | 2023-09-07 | — | — | US | disclosed |
| WO-2009142827-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTION | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-11-26 | — | — | WO | disclosed |
| US-7601703-B2 | Enzyme catalyzed therapeutic agents | CELMED ONCOLOGY (USA), INC. (CA) | 2009-10-13 | — | — | US | disclosed |
| EP-1709056-B1 | PHOSPHORAMIDATE DERIVATIVES | UNIV CARDIFF (GB) | 2009-06-17 | — | — | EP | disclosed |
| US-20090069268-A1 | NOVEL PHOSPHORAMIDATE COMPOUNDS AND METHODS OF USE | CELMED ONCOLOGY (USA), INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2008121634-A2 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PHARMASSET, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20070275910-A1 | Phosphoramidate Derivatives | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070275910-A1 | Phosphoramidate Derivatives | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070265222-A1 | Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection | MERCK SHARP & DOHME CORP. | 2007-11-15 | — | — | US | disclosed |
| US-20070265222-A1 | Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection | MERCK SHARP & DOHME CORP. | 2007-11-15 | — | — | US | disclosed |
| US-20070213307-A1 | Methods to treat autoimmune and inflammatory conditions | CELMED ONCOLOGY (USA), INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069268-A1 | NOVEL PHOSPHORAMIDATE COMPOUNDS AND METHODS OF USE | MTAP, TYMP, INPP5D | BTN3A1 2388/4885MAPK1 1656/4885ANPEP 864/4885 |
| US-20250129112-A1 | Novel Prodrugs Derived from Nicotinic Acid and Ribose | NME4, NADK, NNT | BTN3A1 3722/4885MAPK1 3800/4885ANPEP 2505/4885 |
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | BTN3A1 3601/4885MAPK1 2200/4885ANPEP 359/4885 |
| US-20230279035-A1 | Novel Prodrugs Derived from Nicotinic Acid and Ribose | NME4, NADK, NAMPT | BTN3A1 4110/4885MAPK1 3890/4885ANPEP 2873/4885 |
| US-20070265222-A1 | Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection | NSUN3, NSUN2, PNP | BTN3A1 3346/4885MAPK1 2526/4885ANPEP 281/4885 |
| US-12168673-B2 | Prodrugs derived from nicotinic acid and ribose | NNT, NME4, NADK | BTN3A1 4010/4885MAPK1 3878/4885ANPEP 2319/4885 |
| US-20070213307-A1 | Methods to treat autoimmune and inflammatory conditions | SSB, ENPP2, TPMT | BTN3A1 1069/4885MAPK1 3195/4885ANPEP 1862/4885 |
| US-20070275910-A1 | Phosphoramidate Derivatives | HRH4, HRH3, NR1H4 | BTN3A1 2425/4885MAPK1 1925/4885ANPEP 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.